Moderna Stock Surges as Investors Cheer Earnings and Pipeline Updates

Moderna's stock price jumped 12-15% after the company's investor day, with investors optimistic about the firm's pipeline of treatments. The update raised hopes that the stock price may reach $75 or higher.

MRNA (Moderna) shares surged on June 26, climbing roughly 12% to 15% to a new 12-month high after the company's investor day . The move lifted the stock to a 52-week high near $67.78, reversing some of the weakness that has dogged vaccine names.

The rally followed pipeline updates that investors cheered, particularly progress in Moderna's oncology programs and an update on its CAR-T effort. Management used the event to reframe the company's story around its broader mRNA pipeline rather than its declining COVID-19 franchise, a shift that helped rebuild confidence.

Analysts at Piper Sandler raised their price target to $77 from $69, and bulls floated the prospect of further upside. The durability of the move will depend on clinical readouts and the pace of pipeline execution; Moderna's results still hinge on a relatively small number of high-stakes programs, leaving the stock sensitive to trial outcomes and competition from peers such as MRK (Merck) and PFE (Pfizer).